<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03464760</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2016/APM-01</org_study_id>
    <nct_id>NCT03464760</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect of Spirulina-Silicon Supplementation on the Morphological, Biomechanical and Functional Characteristics of the Arterial Wall in the Elderly</brief_title>
  <acronym>ANGIO SPIRUL</acronym>
  <official_title>Evaluation of the Effect of Spirulina-Silicon Supplementation on the Morphological, Biomechanical and Functional Characteristics of the Arterial Wall in the Elderly</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Phyco-Biotech</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that spirulina-silicon supplementation will lead to an&#xD;
      improvement in vasomotor endothelial function, followed by decreased arterial wave velocity&#xD;
      on the aorta and central arterial pressure compared to placebo subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 22, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arterial Pressure Waveforms between groups</measure>
    <time_frame>Month 6</time_frame>
    <description>Applanation tonometry; m.s-1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial Pressure Waveforms between groups</measure>
    <time_frame>Day 0</time_frame>
    <description>Applanation tonometry; mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Pressure Waveforms between groups</measure>
    <time_frame>Month 1</time_frame>
    <description>Applanation tonometry; mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Pressure Waveforms between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>Applanation tonometry; mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasomotor endothelial function between groups</measure>
    <time_frame>Day 0</time_frame>
    <description>% post-ischemic vasorelaxation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasomotor endothelial function between groups</measure>
    <time_frame>Month 1</time_frame>
    <description>% post-ischemic vasorelaxation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasomotor endothelial function between groups</measure>
    <time_frame>Month 3</time_frame>
    <description>% post-ischemic vasorelaxation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasomotor endothelial function between groups</measure>
    <time_frame>Month 6</time_frame>
    <description>% post-ischemic vasorelaxation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intima-media thickness of common carotid arteries</measure>
    <time_frame>Day 0</time_frame>
    <description>echography; mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intima-media thickness of common carotid arteries</measure>
    <time_frame>Month 6</time_frame>
    <description>echography; mm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left ventricular diastolic function</measure>
    <time_frame>Day 0</time_frame>
    <description>kPa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left ventricular diastolic function</measure>
    <time_frame>Month 6</time_frame>
    <description>kPa</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central venous pressure</measure>
    <time_frame>Day 0</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central venous pressure</measure>
    <time_frame>Month 1</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central venous pressure</measure>
    <time_frame>Month 3</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central venous pressure</measure>
    <time_frame>Month 6</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Pressure Waveforms of females compared to males</measure>
    <time_frame>Month 6</time_frame>
    <description>Applanation tonometry; m.s-1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasomotor endothelial function of females compared to males</measure>
    <time_frame>Month 6</time_frame>
    <description>% post-ischemic vasorelaxation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone density</measure>
    <time_frame>Day 0</time_frame>
    <description>dual-photon absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone density</measure>
    <time_frame>Month 6</time_frame>
    <description>dual-photon absorptiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological markers of vascular remodeling, oxidative stress and inflammation</measure>
    <time_frame>Day 0</time_frame>
    <description>Total cholesterol, High density lipoproteins, Triglycerides, Complete Blood Count, high-sensitivity C-reactive protein, toe systolic pressure, Oxidized low density lipoprotein, Vitamin E, Vitamin C, Reduced (GSH) and Oxidized (GSSG) Glutathione ratio, Procollagen type I N propeptide, cross-linking telopeptide of type I collagen, Elastin, Osteoprotegerin, Sclerotin, Calcium, Phosphorus, Alkaline Bone Phosphatase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological markers of vascular remodeling, oxidative stress and inflammation</measure>
    <time_frame>Month 6</time_frame>
    <description>Total cholesterol, High density lipoproteins, Triglycerides, Complete Blood Count, high-sensitivity C-reactive protein, IsoP, Oxidized low density lipoprotein, Vitamin E, Vitamin C, Reduced (GSH) and Oxidized (GSSG) Glutathione ratio, Procollagen type I N propeptide, cross-linking telopeptide of type I collagen, Elastin, Osteoprotegerin, Sclerotin, Calcium, Phosphorus, Alkaline Bone Phosphatase</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Elderly</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Spirulina-Silicon supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>3.5g of spirulina per day in 1% silicone</intervention_name>
    <description>5 tablets of 700mg per day</description>
    <arm_group_label>Spirulina-Silicon supplementation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>5 tablets per day of potato-based placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The subject must have given their free and informed consent and signed the consent&#xD;
             form&#xD;
&#xD;
          -  The subject must be a member or beneficiary of a health insurance plan&#xD;
&#xD;
          -  The subject is available for 6 months of follow-up&#xD;
&#xD;
          -  The subject must not have any pre-existing chronic illness nor any revealed during the&#xD;
             pre-inclusion visit, either treated or requiring treatment according to current&#xD;
             recommendations&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject is participating in an interventional study, or is in a period of&#xD;
             exclusion determined by a previous study&#xD;
&#xD;
          -  The subject refuses to sign the consent&#xD;
&#xD;
          -  It is impossible to give the subject informed information&#xD;
&#xD;
          -  The patient is under safeguard of justice or state guardianship&#xD;
&#xD;
          -  Presence of a chronic cardio-vascular and/or metabolic illness, known or revealed by&#xD;
             the pre-inclusion exam and requiring treatment in accordance to official&#xD;
             recommendations (HAS)&#xD;
&#xD;
          -  Any other chronic pathology requiring medical treatment&#xD;
&#xD;
          -  History of uric acid metabolism disorders (hyperuricemia, gout, urolithiasis).&#xD;
&#xD;
          -  Subject presenting a loss of limitation of autonomy&#xD;
&#xD;
          -  Treated with hormone replacement therapy in females&#xD;
&#xD;
          -  Active smoker or drug user&#xD;
&#xD;
          -  Presence of an abnormality revealed by the pre-inclusion biological assessment of&#xD;
             dyslipidemia justifying a prescription medication, diabetes or intolerance to glucose&#xD;
             (insulin resistance).&#xD;
&#xD;
          -  Presence of a stenosis (greater than 50% in diameter, NASCET method) or carotid&#xD;
             occlusion revealed by the echo-Doppler screening test.&#xD;
&#xD;
          -  Presence of an aneurysm (dilation&gt; 30 mm) of the abdominal aorta revealed by the&#xD;
             echo-Doppler screening test.&#xD;
&#xD;
          -  Arteriopathy of the lower limbs (toe systolic pressure (tsp) &lt;0.7) revealed by the&#xD;
             screening test (SysToe™ device).&#xD;
&#xD;
          -  Subject already taking a food supplement based on spirulina or silicon.&#xD;
&#xD;
          -  History of cardio-vascular disease or heart attack&#xD;
&#xD;
          -  Subject develops a chronic illness requiring medical treatment for more than 7 days or&#xD;
             a surgical intervention leading to incapacity for more than 7 days,or a pathological&#xD;
             event during the 14-day period before each follow-up visit, or a serious adverse event&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonia Perez-Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonia Perez-Martin, MD</last_name>
    <phone>+33 (0)4 66 68 33 13</phone>
    <email>antonia.perez.martin@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Sarah Coudray, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeremy Laurent, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Eudes Trihan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle Aichoun, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Hampton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 14, 2018</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

